Dermata Therapeutics, Inc. Warrant (DRMAW) Stock Price
DRMAWStock
$0.00
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.28
DRMAW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-109.57%
Price vs S&P 500 (4W)-98.17%
VGM Score0.76
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DRMAWDermata Therapeutics, Inc. Warrant | — | — | F | $0.00 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Dermata Therapeutics, Inc. Warrant
Dermata Therapeutics develops over-the-counter dermatology products for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment combining an OTC-approved active ingredient with its proprietary Spongilla delivery technology. Dermata intends to expand the Spongilla platform across multiple dermatologic and aesthetic applications, including intradermal botulinum toxin delivery.